Contribution of electrocardiography to the diagnosis of cardiomyopathies and athletic heart syndrome

Chumakova O. S., Isaeva M. Yu., Koroleva O. S., Zateyshchikov D. A.

The review describes the role of electrocardiography in the diagnosis of the most common nonischemic myocardial diseases associated with an increased risk of sudden cardiac death, especially in youth sports.

Key words: electrocardiography, cardiomyopathies, athletic heart syndrome, sudden death.

Relationships and Activities. This study was carried out within the grant from the Russian Science Foundation (№ 20-15-00353).

Central State Medical Academy, Administrative Directorate of the President of the Russian Federation, Moscow; Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency, Moscow; City Clinical Hospital № 51, Moscow, Russia.

Chumakova O. S.* ORCID: 0000-0003-2373-1183, Isaeva M. Yu. ORCID: 0000-0003-3548-9937, Koroleva O. S. ORCID: 0000-0001-5646-796X, Zateyshchikov D. A. ORCID: 0000-0001-7065-2045.

*Corresponding author: chumakovaolga@bk.ru

Received: 16.07.2020
Revision Received: 31.07.2020
Accepted: 01.08.2020

For citation: Chumakova O. S., Isaeva M. Yu., Koroleva O. S., Zateyshchikov D. A. Contribution of electrocardiography to the diagnosis of cardiomyopathies and athletic heart syndrome. Russian Journal of Cardiology. 2020;25(S3):4023. (In Russ.) doi:10.15829/1560-4071-2020-4023
Electrocardiography (ECG) is the most accessible and reproducible method for cardiac assessment. For a long time, in nonischemic myocardial diseases, abnormalities in the ECG were considered nonspecific. Recent studies with modern technologies, such as magnetic resonance imaging (MRI) and genetic testing, have made significant progress in understanding pathological processes in the myocardium and defining specific ECG abnormalities for some of them. In cardiomyopathies, ECG abnormalities observed in coronary artery disease and hypertension (HTN) have a different origin and are due to microcirculation disorders, interstitial fibrosis, disorganized cardiomyocytes or their fibro-fatty replacement, as well as asymmetric hypertrophy, changing the QRS axis. The correct interpretation of ECG abnormalities often allows one to promptly assume the true nature of the disease. In some cases, ECG abnormalities are the only phenotypic manifestation of inherited heart disease [1], which makes the method indispensable for family screening.

In athletes, more often in dynamic sports (cycling, football, running), long-term intense exercise leads to structural and electrical adaptive changes, which are commonly called the “athletic heart syndrome” [2]. These changes are benign in most cases, but sometimes they can lead to cardiomyopathies, which are the leading cause of sudden cardiac death (SCD) in young athletes [3]. The correct interpretation of the ECG in athletes, on the one hand, can help to timely diagnose a fatal disease, and on the other hand, to avoid false disqualification [3, 4].

**Arrhythmogenic cardiomyopathy**

Arrhythmogenic cardiomyopathy (ACM), previously defined only as a arrhythmogenic right ventricular (RV) dysplasia, is a genetic disease of the myocardium of RV and/or left ventricle (LV). The distinctive phenotypic feature of ACM is the scarring in the form of fibrous or fibro-fatty replacement of cardiomyocytes which serve as a substrate for global and/or local myocardial dysfunction and predispose to fatal ventricular arrhythmias [5]. The diagnosis of ACM is collective and is based on a combination of morphological, functional, and structural myocardial changes, revealed by echocardiography, MRI, biopsy, resting ECG, and 24-hour ambulatory ECG monitoring. Analysis of family history and genetic testing also plays an important role in the diagnosis of ACM.

On the ECG of ACM patients, there are criteria specific for the predominant involvement of the RV or LV, which are subdivided into major and minor [5]. Thus, inverted T-waves in the right-sided chest leads (V1-V3) in adults without complete right bundle branch block (RBBB) is a major criterion for right-dominant ACM. The spread of inverted T-waves to V4-V6 indicates significant RV dilatation and dysfunction (Figure 1). In the case of complete RBBB, such inversions become less specific and refer to the minor criteria of right-dominant ACM. Also, diseases that may resemble ACM should always be ruled out, such as heart displacement due to pericardiotomy or chest wall deformity, RV volume or pressure overload, cardiac sarcoidosis, and myocarditis [6].

Epsilon wave, previously referred to major ACM criteria, is a reproducible low-amplitude signal between the QRS end and T-wave beginning. Over the past ten years, the diagnostic value of this criterion has been questioned due to its various interpre-

![Figure 1](image-url)
In the 2020 updated Padua criteria [5], the epsilon wave is attributed to the minor criterion of right-dominant ACM, as well as terminal activation duration \( \geq 55 \) ms, measured from the nadir of the S wave to the end of the QRS, including R', in V1, V2, or V3 (in the absence of complete RBBB).

Low QRS voltage in limb leads (<5 mm) may indicate LV involvement in ACM (Figure 1). The sensitivity of this criterion is low (\(<30\%\)); therefore, it is considered minor for the left-dominant ACM in the absence of obesity, emphysema, or pericardial effusion [5]. Also, minor criteria for left-dominant ACM include inverted T waves in left precordial leads (in the absence of complete left bundle branch block (LBBB)) [5]. The isolated left-dominant ACM is phenotypically indistinguishable from dilated cardiomyopathy (DCM) and is often confirmed only by genetic testing.

Registration of late potentials using a signal-averaged ECG has not found wide application in practice and is no longer used for the diagnosis of ACM.

Ventricular arrhythmia with a configuration of complete LBBB and the inferior axis, which indicates its origin from the RV outflow tract is a minor criterion, and without the lower axis, it is a major criterion for right-dominant ACM [5] (Figure 1). Ventricular arrhythmia with a configuration of complete RBBB is a minor criterion for left-dominant ACM [5].

Myocardial changes similar to ACM, such as significant RV enlargement, borderline decrease in the RV ejection fraction (EF), and ventricular arrhythmias, can be induced by regular exercises in healthy individuals [8, 9]. The physiological RV changes on the ECG include voltage criteria for RV hypertrophy, isolated complete RBBB, and right axis deviation.

**Figure 2.** A. The 24-year-old male athlete, pentathlon, asymptomatic. Echocardiography, cardiac MRI, 24-hour ECG monitoring did not reveal any pathology. ECG: inverted T-wave in V1-V3 with preceding ST elevation at J-point >1 mm. B. The 35-year-old female athlete, cycling, asymptomatic, without structural heart disease. ECG: inverted T wave in V1-V3, isolated increase in QRS voltage.

**Figure 3.** The 34-year-old male patient with the apical familial HCM. A. ECG: “giant” inverted T-waves in V2-V6, LV hypertrophy voltage signs. B. Echocardiography: hypertrophy of LV apex with ace-of-spades sign.
Highly sensitive to ACM inversed T-wave, in the right-sided chest leads loses its specificity in athletes due to a fairly high prevalence (up to 4% in V1-V3 and 10% in V1-V2) [2]. According to our unpublished data based on the analysis of 619 ECG records of athletes, inversed T-waves in V1-V3 without any significant structural changes in the heart occur in 1.9% of cases (Figure 2). Nevertheless, today in white athletes, any inversed T-waves in two contiguous leads, including in V1-V3, is regarded as pathological and requires in-depth examination and follow-up. In black athletes, such inversions, especially with ST-segment elevation and a J-point $\geq$1 mm, are referred to as benign [10]. In addition to inversed T-waves, ACM can be suspected in athletes when recording ventricular arrhythmias and epsilon waves.

LV hypertrophy

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease. In 60% of patients, HCM is caused by sarcomere gene mutations. In 5-10%, HCM is simulated by rare storage diseases (Fabry, Danon, PRKAG2 cardiomyopathy), infiltrative diseases (amyloidosis, sarcoidosis), mitochondrial, neuromuscular diseases (Friedreich’s ataxia), malformations (Noonan syndrome), and endocrine cardiomyopathies. In the remaining 30% of patients, the cause of HCM has not yet been clarified [11]. Unlike ACM, the criteria for the HCM diagnosis are only morphological: LV myo-

Figure 4. The 64-year-old female patient with familial transthyretin amyloidosis of the heart. A. ECG: low QRS voltage in limb leads and “normal”, not corresponding to the hypertrophy severity on echocardiography, in the chest leads; R regression in V1-V4. B. Echocardiography: severe LV hypertrophy, atrial dilatation. C. Doppler echocardiography: a restrictive LV diastolic dysfunction.
ECG abnormalities, mainly inverted T-waves or deep narrow (“dagger-like”) Q waves with a positive T wave in the inferior and lateral leads, are recorded in more than 90% of patients with sarcomeric HCM [13]. “Giant” (>10 mm) symmetric T waves, usually present in all chest leads, indicate severe hypertrophy of the LV apex [14] (Figure 3). Pseudo-infarct QS complexes in the chest leads and complete bundle branch blocks occur infrequently in HCM and mainly after surgical reduction of the interventricular septum or in severe transmural fibrosis [13]. Such changes are more typical for infiltrative diseases [15, 16] (Figure 4).

The combination of visually severe LV hypertrophy with conduction abnormalities on the ECG is always suspicious for HCM phenocopies. Thus, a shortened PQ interval should be suggestive of storage [17] or mitochondrial diseases [1], while an atrioventricular conduction delay suggests amyloidosis [15], sarcoidosis [16], or end-stage storage and mitochondrial diseases [1, 13, 17].

In many patients with HCM, voltage criteria for LV hypertrophy are recorded, and only in 2% they are not accompanied by impaired repolarization [18]. If the voltage is very high, then it is worth suspecting the storage disease [13]. If, on the contrary, the QRS voltage is reduced or normal with severe hypertrophy on ECG, then amyloidosis should be suspected [15] (Figure 4).

Every eighth patient with HCM has elongated QT interval ≥480 ms, and every second patient has >450 ms, which is associated with the risk of SCD and is an additional argument for implantation of a cardioverter-defibrillator [13, 19].

About 5-10% of patients with HCM phenotype have either a normal ECG or an isolated increase in QRS voltage. In such patients, the disease debuts later, the symptoms are less pronounced and the prognosis is better [13, 20].

Physiological hypertrophy in athletes does not exceed 14 mm in men [21] and 12 mm in women [22]; nevertheless, it is always suspicious of the HCM onset. One of the most characteristic ECG signs of an athlete’s heart is a pronounced increase in QRS voltage, which is often mistakenly considered as LV hypertrophy. Unlike pathological hypertrophy, there are no concomitant repolarization abnormalities on an athlete’s ECG, therefore, a moderate LV wall thickening on echocardiography in combination with an isolated increase in QRS voltage indicates physiological myocardial remodeling. Repolarization disorders in the form of inverted T wave ≥1 mm in more than 2 contiguous inferior (II and aVF) and, especially, lateral (I, aVL, V5 or V6) leads indicate a possible HCM [4]. Inverted T wave in the inferior and lateral leads are recorded on the ECG of athletes without structural cardiac changes. Isolated T wave inversions in the inferior leads are found in 2% of white and 6% of healthy black athletes [13], which is much more frequent than inherited heart diseases. According to our unpublished data with 1435 ECGs of athletes from various sports, isolated T wave inversions in the inferior leads are found in 1% of cases. Inverted T waves in the lateral leads are considered the most unfavorable, since they may be the first sign of cardiomyopathy [23]. Abnormalities suspicious of HCM in athletes also include pathological Q waves (≥0,25 from the R wave or >40 ms), ST depression ≥0,5 mm in ≥2 contiguous leads, complete LBBB, non-specific prolonged QRS >140 ms, and frequent premature ventricular contractions [4].

**LV systolic dysfunction**

Dilated cardiomyopathy (DCM) is a syndrome characterized by systolic dysfunction and LV dilatation, which cannot be explained by coronary artery disease or conditions leading to LV overload (HTN, valvular and congenital heart disease). LV systolic dysfunction (LVEF <45%) without dilatation since 2016 has been classified as hypokinetic non-dilated cardiomyopathy [24].

DCM is the most etiologically heterogeneous cardiomyopathy. About 40% of DCM cases are inherited [25], which can manifest as isolated heart disease, in combination with conduction defects and noncompacted myocardium (NCM), or within the systemic muscle diseases. Among the latter, the most common DCM phenotype occurs in muscular dystrophies (Duchenne and Becker), limb-girdle muscular dystrophies (LGMD), and Emery-Dreifuss muscular dystrophy (EDMD) [26]. Familial DCM occurs due to mutations in the genes of sarcomere (titin), cytoskeleton (dysferlin, desmin), cell membranes (lamin, ion channels), and organelles [25]. Acquired DCMs develop due to infections, autoimmune diseases, toxic (alcohol, cocaine) or medication (chemotherapy) myocardial damage, micronutrient deficiencies, endocrine and metabolic diseases, and pregnancy [24]. Separately, authors distinguish tachycardia-induced cardiomyopathy — a potentially reversible decrease in LV systolic function, which develops with permanent atrial or ventricular tachyarrhythmia [27]. There is evidence that patients with non-familial DCM also have a genetic substrate of the disease [25, 28-30].

ECG abnormalities are detected in more than 80% of patients with DCM [31]. The most common but nonspecific abnormality is complete LBBB, which sometimes precedes structural changes in...
the heart. It is necessary to distinguish a true complete LBBB from a combination of LV hypertrophy with left anterior fascicular block. With complete LBBB, QRS is ≥140 ms (130 ms for women), there is a notch in the middle QRS part in at least two of the following leads: V1, V2, V5, V6, I, aVL. This morphology is associated with better results of resynchronization therapy [32]. Complete RBBB in DCM is rare and is usually associated with dystrophin gene mutations [31].

Some types of DCM have specific ECG abnormalities. Thus, a reduced P-wave voltage or sick sinus syndrome with an atrial standstill is characteristic of EDMD [24], and sinus bradycardia with sinoatrial arrest episodes is characteristic of laminopathies [31]. AV blocks are associated with mutations in the lamin and sodium channel genes, EDMD, desminopathies, and myotonic dystrophy [24, 26, 31], and among acquired DCMs, they are characteristic of sarcoidosis, Chagas disease, Lyme disease, and diphtheria [24, 31, 33]. Also, in Chagas disease, complete RBBB with left anterior fascicular block is often recorded [34].

‘Posterolateral infarction’ abnormalities are characteristic of dystrophin-related cardiomyopathy, LGMD, and sarcoidosis [1, 24]. Carriers of dystrophin gene mutations can also have a high R-wave voltage in V1-V2 due to transmural scars in the posterolateral LV wall [31].

Voltage signs of LV hypertrophy in patients with DCM phenotype are suspicious for decompensated hypertensive heart disease or end-stage HCM [35]. In a significant proportion of patients with DCM, inverted T-wave are recorded, which, unlike HCM, are less deep, are not associated with voltage criteria for LV hypertrophy, and are not specific [31]. However, a combination of inverted T-wave in the left-sided or in all chest leads with low QRS voltage in limb leads is suspicious for an isolated left-dominated or biventricular ACM [24, 31, 35]. The QT

---

**Table 1**

| Phenotype                        | ECG abnormalities                                      | Suggested diagnosis                                              |
|---------------------------------|--------------------------------------------------------|-----------------------------------------------------------------|
| Dilatation/impaired RV contractility | inverted T in V1-V3                                     | major criterion of right-dominant ACM                           |
|                                 | inverted T in V1-V4(V6)                                  | significant RV involvement                                      |
|                                 | e-wave in V1-V2                                         | minor criterion of right-dominant ACM                           |
|                                 | TAD ≥55 ms in V1-V3                                     | minor criterion of right-dominant ACM                           |
|                                 | ↓ QRS in limb leads                                     | biventricular ACM                                               |
|                                 | inverted T inV4-V6/-I, aVL                              | biventricular ACM                                               |
| LV hypertrophy                  | shortened PQ                                            | Fabry, Danon, Pompe, PRKAG2, mitochondrial diseases            |
|                                 | AV blocks                                               | amyloidosis, end-stage Fabry, Danon, acute myocarditis          |
|                                 | ↑↑ QRS voltage                                          | Danon, Pompe                                                    |
|                                 | ↓ or ‘normal’ QRS voltage                                | amyloidosis                                                     |
|                                 | right QRS axis deviation                                 | Noonan syndrome                                                 |
| LV systolic dysfunction         | ↓ P/atrial standstill                                    | type 1 and 2 EDMD                                               |
|                                 | sinus bradycardia                                       | laminopathy                                                     |
|                                 | shortened PQ                                            | DMD                                                             |
|                                 | AV blocks                                               | sarcoidosis, laminopathy, EDMD, myotonic dystrophy, desminopathy, Chagas disease, diphtheria, Lyme disease |
|                                 | Q/QS in inferolateral leads                             | DMD, BMD, sarcoidosis, LGMD                                     |
|                                 | ↓ QRS                                                   | Left-dominant ACM                                               |
|                                 | Complete RBBB                                           | DMD, Chagas disease (+ left anterior fascicular block)          |
| Hypertrabeculation of LV        | Complete LBBB                                           | NCM                                                             |
|                                 | pathological Q waves                                     |                                                                |
|                                 | inverted T                                              |                                                                |

**Abbreviations:** ACM — arrhythmogenic cardiomyopathy, LV — left ventricle, LBB — left bundle branch, EDMD — Emery-Dreifuss muscular dystrophy, NCM — noncompacted myocardium, RV — right ventricle, LGMD — limb-girdle muscular dystrophies, BMD — Becker muscular dystrophy, DMD — Duchenne muscular dystrophy, TAD — terminal activation delay.
interval in DCM, as a rule, does not change, except for its shortening in the primary carnitine deficiency [36] or lengthening in anthracycline-related cardiomyopathy [31]. As with HCM, ~10% of patients with the DCM phenotype have a normal ECG [35].

Every 10th athlete in dynamic sports develops a significant LV enlargement with a decrease in EF (<52%) [21]. Such LV remodeling in combination with severe bradycardia and/or a significant PQ interval lengthening (up to 400 ms), which are characteristic of a athlete’s heart, complicates the differential diagnosis with DCM. The presence of high-grade AV conduction disorders in athletes, complete LBBB, impaired repolarization in the lateral leads, pathological Q waves or ventricular arrhythmias in combination with decreased LVEF are always suspicious for pathological cardiomyopathy [4].

Hypertrabeculation/LV NCM
NCM is characterized by hypertrabeculation of the LV with deep intertrabecular recesses communicating with the LV cavity and is clinically associated with heart failure, ventricular arrhythmias, and systemic thromboembolism [37]. Due to the widespread use of MRI, the morphological criteria of NCM is detected quite often (up to 15%) in the general population [38], which made it obvious the need to differentiate the true NCM caused by mutations in the genes of the sarcomere, cytoskeleton, mitochondria, cell membranes, and others [39], from benign LV hypertrabeculation. ECG can help with differential diagnosis. Thus, the detection of early repolarization pattern translates LV hypertrabeculation into the ‘grey zone’ of NCM, and registration of complete LBBB, pathological Q waves, or inverted T wave indicates a high risk of pathological NCM [37].

In the population of athletes, excessive trabeculation is quite common due to increased LV preload during exercise, which unmasks the trabeculae and makes them more pronounced [40]. The same mechanism explains the significantly higher prevalence of NCM among patients with chronic anemia and pregnant women [41, 42]. Most athletes with LV hypertrabeculation have a benign isolated increase in QRS voltage or early ventricular repolarization pattern. Nevertheless, a small part (0.9%) has an inverted T wave and reduced LV systolic function, which should be interpreted as pathology [43].

Conclusion
Various clinical courses of cardiomyopathies make it difficult to make an accurate diagnosis and stratify the risk of SCD. ECG abnormalities may help to suggest the nature of nonischemic structural changes of the heart and thereby reduce the time to diagnosis, identify patients who require the implantable cardioverter-defibrillator, or promptly initiate specific therapy. Among a large number of asymptomatic healthy athletes, the ECG makes it possible to single out those who require more careful monitoring. Increasing the knowledge level on the ECG interpretation in cardiomyopathies will improve the detection, treatment, and prognosis of such patients. Summary data on specific ECG abnormalities in cardiomyopathies are presented in Table 1.

Relationships and Activities. This study was carried out within the grant from the Russian Science Foundation (№ 20-15-00353).

References
1. Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(19):1448-58. doi:10.1093/eurheartj/ehs397.
2. Brosnan M, La Gerche A, Kalman J, et al. Comparison of frequency of significant electrocardiographic abnormalities in endurance versus nonendurance athletes. Am J Cardiol. 2014;113(9):1567-73. doi:10.1016/j.amjcard.2014.01.438.
3. Corrado D, Basso C, Rizzoli G, et al. Does Sports Activity Enhance the Risk of Sudden Death in Adolescents and Young Adults? JACC. 2003;42(11):1959-63. doi:10.1016/j.jacc.2003.03.002.
4. Sharma S, Drezner JA, Baggish A, et al. International Recommendations for Electrocardiographic Interpretation in Athletes. J Am Coll Cardiol. 2017;69(8):1057-75. doi:10.1016/j.jacc.2017.01.015.
5. Corrado D, Marra MP, Zorzi A, et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. Int J Cardiol. 2020. doi:10.1016/j.ijcard.2020.06.005.
6. Quarta G, Husain SI, Flett AS, et al. Arrhythmogenic right ventricular cardiomyopathy mimics: role of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013;15:16. doi:10.1186/1532-429X-15-16.
7. Platonov PG, Calkins H, Hauer RN, et al. High interobserver variability in the assessment of epsilon waves: Implications for diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm. 2016;13(1):208-16. doi:10.1016/j.hrthm.2015.08.031.
8. La Gerche A, Claessen G, Dymarkowski S, et al. Exercise-induced right ventricular dysfunction is associated with ventricular arrhythmias in endurance athletes. Eur Heart J. 2015;36(30):1998-2010. doi:10.1093/eurheartj/ehv202.
9. Zaidi A, Ghani S, Sharma R, et al. Physiological right ventricular adaptation in elite athletes of African and Afro-Caribbean origin. Circulation. 2013;127(17):1783-92. doi:10.1161/CIRCULATIONAHA.112.000270.
10. Finocchiaro G, Papadakis M, Dhuita H, et al. Electrocardiographic differentiation between ‘benign T-wave inversion’ and arrhythmogenic right ventricular cardiomyopathy. Europace. 2019;21(2):332-8. doi:10.1093/europace/euy179.
11. Seferovic PM, Pololova M, Bausersachs J, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(5):553-76. doi:10.1002/ejhf.1461.
12. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.
13. Finocchiaro G, Sheik N, Biagini E, et al. The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Heart Rhythm. 2020;17(1):142-51. doi:10.1016/j.hrthm.2019.07.019.

14. Dumont CA, Monserrat L, Soler R, et al. Interpretation of electrocardiographic abnormalities in hypertrophic cardiomyopathy with cardiac magnetic resonance. Eur Heart J. 2006;27(14):1725-31. doi:10.1093/eurheartj/ehl101.

15. Bart NK, Thomas L, Korczyk D, et al. Amyloid Cardiomyopathy. Heart Lung Circ. 2020;29(4):575-83. doi:10.1016/j.hlc.2019.11.019.

16. Birnie DH, Nery PB, Ha AC, et al. Cardiac Sarcoidosis. J Am Coll Cardiol. 2016;68(4):411-21. doi:10.1016/j.jacc.2016.03.005.

17. Lopez-Sainz A, Dominguez F, Lopes LR, et al. Clinical Features and Natural History of PRKAG2 Variant Cardiomyosis. J Am Coll Cardiol. 2020;76(2):186-97. doi:10.1016/j.jacc.2020.05.029.

18. Calore C, Melacini P, Pelliccia A, et al. Prevalence and clinical meaning of isolated increase of QRS voltages in hypertrophic cardiomyopathy versus athlete’s heart: relevance to athletic screening. Int J Cardiol. 2013;168(4):4494-7. doi:10.1016/j.ijcard.2013.06.123.

19. Patel SI, Ackerman MJ, Shamoun FE, et al. QT prolongation and sudden cardiac death risk in hypertrophic cardiomyopathy. Acta Cardiol. 2019;74(1):53-8. doi:10.1080/00184078.2018.1440905.

20. McLeod CJ, Ackerman MJ, Nishimura RA, et al. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll Cardiol. 2009;54(3):229-33. doi:10.1016/j.jacc.2009.02.071.

21. Abergel E, Chatellier G, Hagege AA, et al. Serial left ventricular adaptations in world-class professional cyclists: implications for disease screening and follow-up. J Am Coll Cardiol. 2004;44(1):144-9. doi:10.1016/j.jacc.2004.02.057.

22. Pelliccia A, Maron BJ, Calasso F, et al. Athlete’s heart in women. Echocardiographic characterization of highly trained elite female athletes. JAMA. 1996;276(2):211-5. doi:10.1001/jama.1996.03500260007025.

23. Pelliccia A, Di Paolo FM, Quattrini FM, et al. Outcomes in athletes with marked ECG repolarization abnormalities. N Engl J Med. 2008;358(2):152-61. doi:10.1056/NEJMoa060783.

24. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850-8. doi:10.1093/eurheartj/ehv727.

25. Gambino N, Fagard R, Puddu PE, et al. Impact of diabetes on cardiovascular disease in athletes: a joint task force of the European Society of Cardiology (ESC) and the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J. 2013;34(4):2460-9. doi:10.1093/eurheartj/eht151.

26. Franzetti G, Cattaneo BM, Breganti A, et al. Effect of exercise training on left ventricular geometry and function in patients with diabetes: a randomized controlled trial. JAMA. 2010;304(4):442-9. doi:10.1001/jama.2010.933.

27. Martin CA, Lambiase PD. Pathophysiology, diagnosis and treatment of tachycardiacardomyopathy. Heart Rhythm. 2020;17(3):274-81. doi:10.1016/j.hrtm.2020.01.044.

28. Garcia-Pavia P, Kim Y, Restrepo-Cordoba M, et al. Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation. 2019;140(1):31-41. doi:10.1161/CIRCULATIONAHA.118.037934.

29. Ware JS, Li J, Mazaika E, et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med. 2016;374(3):233-41. doi:10.1056/NEJMoa1505517.

30. Ware JS, Amor-Salamanca A, Tayal U, et al. Genetic Etiology for Alcohol-Induced Cardiac Toxicity. J Am Coll Cardiol. 2018;71(20):2293-302. doi:10.1016/j.jacc.2018.03.462.

31. Finocchiaro G, Merlo M, Sheikh N, et al. The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy. Eur J Heart Fail. 2020. doi:10.1002/ejhf.1815.

32. Strauss DG, Selvester RH, Wagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy. Am J Cardiol. 2011;107(6):927-34. doi:10.1016/j.amjcard.2010.11.010.

33. Nery PB, Beanlands RS, Nair GM, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol. 2014;25(8):875-81. doi:10.1111/jce.12401.

34. Nunes MCP, Beaton A, Acquatella H, et al. Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. Circulation. 2018;138(12):e169-e209. doi:10.1161/CIR.0000000000000599.

35. Merlo M, Zaffalon D, Stolfo D, et al. ECG in dilated cardiomyopathy: specific findings and long-term prognostic significance. J Cardiovasc Med (Hagerstown). 2019;20(7):450-8. doi:10.2459/JCM.0000000000000804.

36. Perin F, Rodriguez-Vazquez Del Rey MDM, Carreras-Blesa C, et al. Dilated Cardiomyopathy With Short QT Interval: ECG Correlates of tachycardiacardomyopathy. J Cardiovasc Med (Hagerstown). 2018;19(1):1-8. doi:10.2459/JCM.0000000000000924.

37. D’Ascenzi F, Pelliccia A, Natali BM, et al. Exercise-induced left-ventricular noncompaction phenotype, noncompaction phenotype and left ventricular noncompaction cardiomyopathy. J Cardiovasc Med (Hagerstown). 2020;21(3):192-9. doi:10.2459/JCM.0000000000000924.

38. Welt-McCull JR, Yeap PM, Papagiorcopolu G, et al. Left Ventricular Noncompaction: Anatomical Phenotype or Distinct Cardiomyopathy? J Am Coll Cardiol. 2016;68(20):2157-65. doi:10.1016/j.jacc.2016.08.054.

39. van Waning JI, Caliskan K, Hoedemaekers YM, et al. Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy. J Am Coll Cardiol. 2018;71(7):711-22. doi:10.1016/j.jacc.2017.12.019.

40. D’Ascenzi F, Pelliccia A, Natali BM, et al. Exercise-induced left-ventricular hypertrabeculation in athlete’s heart. Int J Cardiol. 2015;181:320-2. doi:10.1016/j.ijcard.2014.11.023.

41. Gati S, Papadakis M, Papamichael ND, et al. Reversible de novo left ventricular trabeculations in pregnant women: implications for the diagnosis of left ventricular noncompaction in low-risk populations. Circulation. 2014;130(6):475-83. doi:10.1161/CIRCULATIONAHA.114.08554.

42. Gati S, Papadakis M, Van Niekert N, et al. Increased left ventricular trabeculation in individuals with sickle cell anaemia: physiology or pathology? Int J Cardiol. 2013;168(2):1585-60. doi:10.1016/j.ijcard.2013.03.039.

43. Gati S, Chandra N, Bennett RL, et al. Increased left ventricular trabeculation in highly trained athletes: do we need more stringent criteria for the diagnosis of left ventricular non-compaction in athletes? Heart. 2013;99(7):506. doi:10.1136/heartjnl-2012-303418.